The IND application of IBI3032 was accepted by China’s National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical ...

Q2 2025 Management View Andrew Dudum, CEO, highlighted the platform’s rapid growth, noting, “At the end of the second quarter, we were serving over 2.4 million subscribers on our platform with nearly ...

Pancreatitis, vision loss ... the risks of drugs such as Ozempic can sound scary. But what does the evidence show?